Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06900998 · ClinicalTrials.gov registry record · Phase 2
Pilot Study: Effects of Nimodipine on Alcohol Drinking
A Phase 2 study, sponsored by Yale University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT06900998 is a Phase 2 study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT06900998, a Phase 2 study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipine 90 mg/dose every six hours during an 18-hour period prior to the ADP to allow for the limited central nervous system bioavailability of this drug. Electroencephalogram (EEG) data will be collected before the first dose and after the last dose of nimodipine. Adverse events will be closely monitored during this period. During the ADP session participants will receive a priming dose of alcohol followed by a one-hour monitoring period. This will be followed by three one-hour self-administration periods; during each hour, participants will be able to choose between drinking up to four drinks or receive the monetary equivalents of these drinks (total of 12 drinks over three hours).
Interventions
- DRUG Nimodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06900998
The ClinicalTrials.gov registry entry for NCT06900998 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nimodipine is the first listed.
NCT06900998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06900998 about?
NCT06900998 is a clinical study titled "Pilot Study: Effects of Nimodipine on Alcohol Drinking". This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipin...
What is the current status of trial NCT06900998?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2026-09-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT06900998?
The interventions under investigation include: Nimodipine (DRUG).
Who is sponsoring clinical trial NCT06900998?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.